The FDA has warned about heart failure with alogliptin and saxagliptin, and the question has hung over the class since. This review pooled 29 randomised trials covering 67,873 patients with type 2 diabetes, with and without existing cardiovascular disease, under a random-effects model.
Across the class there was no association: risk ratio 1.06 (95% CI 0.94 to 1.12). Subgroup analysis by individual drug did find a significant association for saxagliptin. The authors are notably cautious about their own result, citing several limitations, and the certainty of evidence was graded rather than assumed.
Why it matters: it separates a class effect from a drug effect. "DPP-4 inhibitors cause heart failure" and "saxagliptin may" lead to different prescribing, and the second is much narrower than the caution the class has carried.
What to do about it: for a patient stable on sitagliptin or linagliptin with heart failure in the background, this is reassurance rather than a reason to switch. For saxagliptin the older caution stands, and where an alternative is easy the alternative is reasonable. Subgroup findings are the weakest part of any meta-analysis, so this is a signal to weigh, not a verdict.
- No class-wide heart failure signal across 29 trials and 67,873 patients
- Saxagliptin was the exception in subgroup analysis — treat with the existing caution
- Not a reason to stop sitagliptin or linagliptin in stable patients
- Subgroup results are hypothesis-generating; the authors flag their own limitations
- Where an SGLT2 inhibitor is indicated for heart failure, that decision is unaffected
The statistics, in plain English
A risk ratio of 1.06 with a confidence interval of 0.94 to 1.12 spans 1.0, meaning no difference is well within what the data support — and the interval is narrow, so this is a large body of evidence finding nothing rather than a small one that could not tell. The saxagliptin subgroup deserves more scepticism than the headline: subgroups are smaller, and testing several drugs separately makes one crossing the significance threshold likely by chance alone. It is consistent with the older SAVOR-TIMI signal, which is what stops it being dismissible.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free